首页> 外文期刊>Molecular cancer research: MCR >EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression.
【24h】

EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression.

机译:通过抑制p21 / CDKN1A表达,黑素瘤细胞中EZH2依赖性细胞衰老表型的抑制。

获取原文
获取原文并翻译 | 示例
           

摘要

Polycomb group (PcG) proteins such as Enhancer of zeste homolog 2 (EZH2) are epigenetic transcriptional repressors that function through recognition and modification of histone methylation and chromatin structure. Targets of PcG include cell cycle regulatory proteins which govern cell cycle progression and cellular senescence. Senescence is a characteristic of melanocytic nevi, benign melanocytic proliferations that can be precursors of malignant melanoma. In this study, we report that EZH2, which we find absent in melanocytic nevi but expressed in many or most metastatic melanoma cells, functionally suppresses the senescent state in human melanoma cells. EZH2 depletion in melanoma cells inhibits cell proliferation, restores features of a cellular senescence phenotype, and inhibits growth of melanoma xenografts in vivo. p21/CDKN1A is activated upon EZH2 knockdown in a p53-independent manner and contributes substantially to cell cycle arrest and induction of a senescence phenotype. EZH2 depletion removes histone deacetylase 1 (HDAC1) from the CDKN1A transcriptional start site and downstream region, enhancing histone 3 acetylation globally and at CDKN1A. This results in recruitment of RNA polymerase II, leading to p21/CDKN1A activation. Depletion of EZH2 synergistically activates p21/CDKN1A expression in combination with the HDAC inhibitor trichostatin A. Since melanomas often retain wild-type p53 function activating p21, our findings describe a novel mechanism whereby EZH2 activation during tumor progression represses p21, leading to suppression of cellular senescence and enhanced tumorigenicity. Mol Cancer Res; 9(4); 418-29. (c)2011 AACR.
机译:聚梳组(PcG)蛋白(如zeste同源物2的增强子(EZH2))是表观遗传转录抑制子,其通过识别和修饰组蛋白甲基化和染色质结构起作用。 PcG的靶标包括控制细胞周期进程和细胞衰老的细胞周期调节蛋白。衰老是黑素细胞痣的特征,良性黑素细胞增殖可能是恶性黑色素瘤的前体。在这项研究中,我们报告说,我们发现黑素细胞痣中不存在但在许多或大多数转移性黑素瘤细胞中表达的EZH2在功能上抑制了人类黑素瘤细胞的衰老状态。黑色素瘤细胞中EZH2耗竭抑制细胞增殖,恢复细胞衰老表型的特征,并抑制体内黑色素瘤异种移植物的生长。 p21 / CDKN1A在EZH2敲低后以p53独立的方式被激活,并实质上有助于细胞周期停滞和衰老表型的诱导。 EZH2耗竭从CDKN1A转录起始位点和下游区域去除组蛋白脱乙酰基酶1(HDAC1),从而增强了全局和CDKN1A处的组蛋白3乙酰化。这导致RNA聚合酶II的募集,导致p21 / CDKN1A激活。 EZH2的耗竭与HDAC抑制剂曲古抑菌素A协同激活p21 / CDKN1A表达。由于黑素瘤通常保留激活p21的野生型p53功能,因此我们的发现描述了一种新颖的机制,在肿瘤进展过程中EZH2激活可抑制p21,从而抑制细胞衰老和增强的致瘤性。分子癌症研究; 9(4); 418-29。 (c)2011年美国机修协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号